Summary
Milrinone, a new, nonglycosidic inotropic agent with peripheral vasodilating properties, was given as a single oral 5 mg dose to 7 healthy subjects, 7 patients with moderate renal impairment (CRI I, creatinine clearance 30–63 ml/min) and 7 patients with severe renal impairment (CRI II, creatinine clearance 9–29 ml/min). All except one of the patients with renal impairment had hypertension. The mean urinary recovery of milrinone was 82% in healthy subjects, the renal clearance was 288 ml/min and the plasma half-life (t1/2) was 0.94 h. In CRI the mean plasma t1/2 was prolonged (CRI I 1.78 h, CRI II 3.24 h). There was a significant linear relationship between creatinine clearance and the elimination rate constant, and between creatinine clearance and the renal clearance of milrinone. During the study day there was a tendency to a decrease in supine BP from 1 to 6–8 h after dosing, with the maximal decrease at 2–3 h (healthy subjects 118/71→107/56, CRI 159/95→136/79 mmHg). The same degree of change was seen in standing BP. A slight rise in standing HR was seen from 2–6 h after dosing. Changes in BP and HR are difficult to evaluate since the study was not placebo-controlled.
The plasma elimination rate of milrinone was decreased in CRI and dose adjustment may be necessary. Placebo-controlled studies of milrinone in hypertensive patients would be required to validate its possible antihypertensive effect.
Similar content being viewed by others
References
Baim DS, McDowell AV, Cherniles J, Monrad EC, Parker JA, Edelson J, Braunwald E, Grossman W (1983) Evaluation of a new bipyridine inotropic agent — milrinone — in patients with severe congestive heart failure. N Engl J Med 309: 748–756
Maskin CS, Sinoway L, Chadwick RN, Sonnenblick EH, Le Jemtel TH (1983) Sustained hemodynamic and clinical effects of a new cardiotonic agent WIN 47203, in patients with severe congestive heart failure. Circulation 67: 1065–1070
Sinoway LS, Maskin CS, Chadwick B, Forman R, Sonnenblick EH, Le Jemtel TH (1983) Long-term therapy with a new cardiotonic agent, WIN 47203: Drug-dependent improvement in cardiac performance and progression of the underlying disease. J Am Coll Cardiol 2: 327–331
Stroshane RM, Koss RF, Biddlecome CE, Luczkowec C, Edelson J (1984) Oral and intravenous pharmacokinetics of milrinone in human volunteers. J Pharm Sci 73: 1438–1441
Stroshane RM, Benziger DP, Edelson J (1984) Pharmacokinetics of milrinone in congestive heart failure patients. In: Braunwald E, Sonnenblick EH, Chakrin LW, Schwarz RP (eds) Milrinone: Investigation of new inotropic therapy for congestive heart failure, Raven Press, New York, pp 119–131
Edelson J, Koss RF, Baker JF, Park GB (1983) High performance liquid chromatographic analysis of WIN 47, 203 in plasma and urine. Intravenous pharmacokinetics in the dog. J Chromatogr 276: 456–462
Baker JF, Edelson J (1984) Metabolism and pharmacokinetics of milrinone in laboratory animals. In: Braunwald E, Sonnenblick EH, Chakrin LW, Schwarz RP (eds) Milrinone: Investigation of new inotropic therapy for congestive heart failure. Raven Press, New York, pp 49–53
Cody RJ, Chatterjee K, Kubo SH, Simonton C, Rutman H (1984) Ascending dose-range study of oral milrinone in chronic congestive heart failure. In: Braunwald E, Sonnenblick EH, Chakrin LW, Schwarz RP (eds) Milrinone: Investigation of new inotropic therapy for congestive heart failure. Raven Press, New York, pp 109–117
Baim DS, Monrad ES, McDowell AV, Smith H, Lanoue A, Braunwald E, Grossman W (1984) Milrinone therapy in patients with severe congestive heart failure; Initial hemodynamic and clinical observations. In: Braunwald E, Sonnenblick H, Chakrin LW, Schwarz RP (eds) Milrinone: Investigation of new inotropic therapy for congestive heart failure. Raven Press, New York, pp 143–153
Alousi AA, Canter JM, Cicero F, Fort DJ, Helstosky A, Lesher GY, Montenaro MJ, Stankus GP, Stuart JC, Walton LH (1984) Pharmacology of milrinone. In: Braunwald E, Sonnenblick EH, Chakrin LW, Schwarz EP (eds) Milrinone: Investigation of new inotropic therapy for congestive heart failure, Raven Press, New York, pp 21–48
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Larsson, R., Liedholm, H., Andersson, K.E. et al. Pharmacokinetics and effects on blood pressure of a single oral dose of milrinone in healthy subjects and in patients with renal impairment. Eur J Clin Pharmacol 29, 549–553 (1986). https://doi.org/10.1007/BF00635891
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00635891